CHKB: A Potential Drug Target and Biomarker (G1120)

Target Name: CHKB

NCBI ID: G1120

CHKB

CHKB: A Potential Drug Target and Biomarker

CHKB (CKEKB) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. CHKB is a gene that encodes a protein known as CKB, which plays a critical role in the regulation of cell growth, apoptosis, and inflammation.

Studies have shown that CHKB is highly expressed in various tissues and organs, including brain, heart, liver, and muscle. It is also expressed in various types of cancer, including breast, ovarian, and colorectal cancer. In addition, CHKB is also expressed in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, as well as in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

One of the key functions of CHKB is its role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. CHKB has been shown to play a critical role in the regulation of apoptosis, by promoting the clearance of damaged or dysfunctional cells and by inhibiting the survival of cells that have been damaged by environmental stressors, such as radiation or chemicals.

In addition to its role in apoptosis, CHKB has also been shown to play a critical role in the regulation of cell growth and development. It has been shown to promote the growth and proliferation of normal cells, while inhibiting the growth and proliferation of cancer cells. This is important because the regulation of cell growth and development is critical for the development and progression of various diseases, including cancer.

Another function of CHKB is its role in inflammation. It has been shown to play a critical role in the regulation of inflammatory responses, by promoting the production of pro-inflammatory cytokines and by inhibiting the production of anti-inflammatory cytokines. This is important because inflammation is a critical factor in the development and progression of many diseases, including autoimmune disorders and cancer.

In conclusion, CHKB is a gene that has been identified as a potential drug target and biomarker for various diseases. Its functions in cell apoptosis, growth and development, and inflammation make it an attractive target for drug development. Further research is needed to fully understand the role of CHKB in disease and to develop safe and effective drugs that target it.

Protein Name: Choline Kinase Beta

Functions: Has a key role in phospholipid metabolism, and catalyzes the first step of phosphatidylethanolamine and phosphatidylcholine biosynthesis

The "CHKB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHKB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets